Review Article

AYURVEDIC REVIEW ON AMAVATA WITH SPECIAL REFERENCE TO RHEUMATOID ARTHRITIS

Dr. Neha Tiwari, *M.D. (Kayachikitsa), AYUSH Medical Officer, Dispensary, Dahigaon, Padampur, Odisha, India*

Received:
28/09/2026

Received in Revised Form:
30/10/2026

Accepted:
31/10//2026

Published:
03/11/2026

Corresponding Author:
Dr. Neha Tiwari, M.D. (Kayachikitsa), AYUSH Medical Officer, PHC, Dahita, Padampur, Odisha, India

Email:
nehatiwaritn97@gmail.com

How to Cite this Article

Tiwari N. Ayurvedic review on Amavata with special reference to rheumatoid arthritis. Ekansh Journal of Nursing, Public Health & Medical Sciences. 2026;1(2):01–08

ABSTRACT

Background: Amavata is a musculoskeletal disorder described in Ayurvedic literature and is associated traditionally with Ama and aggravated Vata. Its described manifestations include joint pain, swelling, stiffness and functional limitation. These features overlap with some manifestations of rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease; however, the conditions arise from different conceptual and diagnostic frameworks.

Objective: To review the Ayurvedic concept, proposed etiopathogenesis, clinical manifestations and management principles of Amavata; examine its clinical correlation with RA; and critically summarize the available clinical evidence and research gaps.

Materials and Methods: A narrative review was prepared using classical Ayurvedic texts and published literature concerning Amavata, Ayurvedic interventions, assessment of Ama, and contemporary RA diagnosis and management. The literature was considered descriptively, with attention to relevance, study design, reported outcomes and methodological limitations. The review was not designed as a systematic review or meta-analysis.

Discussion: Ayurvedic descriptions emphasize impaired Agni, formation of Ama, aggravation of Vata and localization of the pathological process in the joints. Traditional management principles include Nidana Parivarjana, Langhana, Deepana-Pachana, Shodhana and Shamana approaches, selected according to the individual and disease stage. Published clinical studies have reported improvements following selected interventions, but the evidence is limited by differences in study designs, sample sizes, interventions, outcome measures and follow-up. Research has also explored structured assessment of Ama and its relationship with conventional measures of RA disease activity. Such findings are preliminary and do not establish diagnostic equivalence or therapeutic effectiveness.

Conclusion: Amavata and RA share some clinical manifestations but should not be considered identical diagnostic entities. The available evidence supports further rigorous investigation rather than definitive claims about the effectiveness of Ayurvedic interventions. Future studies should use reproducible Ayurvedic criteria, validated rheumatological outcomes, adequate follow-up and systematic safety monitoring. Ayurvedic approaches, where considered, should complement rather than replace appropriate RA diagnosis and evidence-based treatment.

(Keywords: Amavata; Ayurveda; Ama; rheumatoid arthritis; Vata; clinical review; integrative research

INTRODUCTION

Amavata is described in Ayurvedic literature as a disorder in which Ama is associated with aggravated Vata and the pathological process becomes manifest predominantly in the joints. Classical descriptions include joint pain, swelling, stiffness, tenderness and restricted movement, with other features such as heaviness, reduced appetite, fatigue and digestive complaints also described in Ayurvedic accounts [1,2]. Within Ayurveda, these manifestations are interpreted through concepts including Agni, Ama, Dosha, Srotas and Samprapti.

Some manifestations of Amavata resemble those observed in rheumatoid arthritis (RA), including inflammatory joint pain, swelling, stiffness and functional limitation. RA, however, is a chronic systemic inflammatory autoimmune disease associated with persistent synovial inflammation and potential structural joint damage. Its assessment is based on clinical evaluation supported, where indicated, by serological, inflammatory and imaging investigations [3,4,10]. Therefore, similarity in symptoms does not demonstrate that Amavata and RA are the same disease or share an identical pathophysiology.

This review addresses four questions: (1) how is Amavata described in classical Ayurvedic literature; (2) which clinical features overlap with those of RA, and what are the limits of that comparison; (3) what Ayurvedic management principles and interventions have been discussed in the published literature; and (4) how strong is the available clinical evidence, and what research is needed? These questions are relevant because the term "Amavata" is often discussed with reference to RA, while meaningful interdisciplinary research requires clear distinctions between traditional explanatory concepts and established biomedical diagnosis.

The review therefore presents the Ayurvedic framework and contemporary understanding of RA separately, summarizes selected clinical research cautiously, and considers the implications for safe clinical practice. Modern RA management emphasizes early diagnosis and timely disease-modifying antirheumatic drug (DMARD) therapy to control disease activity and reduce the risk of joint damage [5]. Any consideration of Ayurvedic approaches in people with suspected or confirmed RA must retain this clinical priority.

AIM OF THE STUDY

Aim

To review the Ayurvedic concept, proposed etiopathogenesis and management of Amavata, and examine its clinical correlation with rheumatoid arthritis in light of available contemporary evidence.

Objectives

1. To describe the Ayurvedic concept, etiopathogenesis and clinical manifestations of Amavata.

2. To compare selected clinical manifestations of Amavata with those of RA while distinguishing their diagnostic and explanatory frameworks.

3. To summarize Ayurvedic management principles and published clinical investigations concerning Amavata.

4. To critically discuss the strength and limitations of the available evidence and identify priorities for future research.

MATERIALS AND METHODS

This article was prepared as a narrative review. Classical Ayurvedic texts addressing Amavata, Ama, Vata, Agni, Samprapti and related management principles were considered alongside published scientific literature concerning RA, Ayurvedic interventions studied in Amavata, and research on the assessment of Ama [1–12]. The sources cited in this review include classical texts, clinical studies, research on an Ama assessment instrument, and contemporary literature on RA pathogenesis, classification and management.

The literature was considered descriptively according to its relevance to the review questions, clinical context, study design, reported outcomes and limitations. The review discusses the findings of selected published studies but does not claim to provide an exhaustive search of all available literature. A formal systematic search strategy, duplicate screening, risk-of-bias assessment and meta-analysis were not undertaken. Accordingly, the findings should be interpreted as a narrative synthesis rather than a systematic evaluation of treatment efficacy.

AYURVEDIC CONCEPT OF AMAVATA

4.1 Ayurvedic explanation and proposed etiopathogenesis

In the Ayurvedic framework, proper functioning of Agni is considered important for digestion and physiological transformation. Impairment of Agni is described as contributing to the formation of Ama. When Ama is associated with aggravated Vata and the pathological process involves the joints, the resulting condition is described as Amavata [1,2]. This is a traditional explanatory model and should not be equated with the biomedical mechanisms established for RA.

4.2 Nidana

Classical Ayurvedic descriptions associate Amavata with factors considered to impair digestion and promote Ama formation. These include inappropriate dietary practices, irregular eating patterns, excessive intake of heavy or poorly tolerated foods and certain lifestyle patterns [1,2]. Such descriptions should be presented as Ayurvedic concepts; they do not, by themselves, establish biomedical causes of rheumatoid arthritis.


4.3 Purvarupa

Features described as early or associated manifestations may include reduced appetite, indigestion, heaviness, generalized discomfort, fatigue and weakness [1,2]. The interpretation of these symptoms within Ayurveda should be distinguished from the clinical criteria used to diagnose RA.

4.4 Rupa (clinical manifestations)

The principal manifestations described for Amavata include joint pain, swelling, stiffness, tenderness and restricted movement. Other reported features may include heaviness, weakness, reduced appetite, generalized discomfort and feverishness [1,2]. These symptoms can overlap with inflammatory joint disorders, but they are not specific to RA and should not be used alone to establish a biomedical diagnosis.

4.5 Samprapti



4.6 Samprapti Ghataka

The principal components commonly discussed in the Ayurvedic account of Amavata include:

Dosha: Predominantly Vata, with other Doshas considered according to the individual presentation.

Dushya: Tissues and structures considered involved in the disease process.

Agni: Impaired Jatharagni in the traditional explanation.

Ama: A central pathological concept in the Ayurvedic model.

Srotas: Channels described as involved in nourishment and tissue function.

Sthana: Sandhi (joints).

Rogamarga: Madhyama Rogamarga, particularly in relation to musculoskeletal involvement.

These categories organize the Ayurvedic interpretation of Amavata and should not be treated as direct equivalents of biomedical anatomical or immunological mechanisms [1,2].

CLINICAL CORRELATION WITH RHEUMATOID ARTHRITIS

5.1 Contemporary understanding of RA

RA is a chronic systemic inflammatory autoimmune disease characterized by persistent synovitis. Ongoing inflammation may result in cartilage damage, bone erosion, joint deformity and functional impairment. Its pathogenesis involves interactions among genetic susceptibility, environmental influences and dysregulated innate and adaptive immune responses [3,4]. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) may support diagnosis and provide prognostic information, but results must be interpreted in the context of the clinical presentation.

5.2 Areas of clinical overlap and important distinctions

Amavata and RA may share joint pain, swelling, stiffness, tenderness and limitation of movement. Fatigue and reduced functional capacity may also occur in people with RA and may be described in accounts of Amavata [1–4,6–9]. This overlap supports comparative clinical discussion, but it does not establish that the two are identical.

The Ayurvedic account explains Amavata through Ama, Agni, Dosha, Srotas and Samprapti. RA is evaluated using contemporary clinical criteria and, where appropriate, laboratory and imaging findings.

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria consider joint involvement, serology, acute-phase reactants and symptom duration in people with clinically evident synovitis [10]. These are classification criteria and do not replace individualized clinical diagnosis.

5.3 Diagnosis and differential diagnosis

Suspected RA requires appropriate medical evaluation. Assessment may include history, physical examination, RF, ACPA, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and imaging when clinically indicated [10]. No single laboratory test should be interpreted in isolation, and alternative causes of inflammatory arthritis must be considered. The differential diagnosis may include psoriatic arthritis, gout, systemic lupus erythematosus, viral or reactive arthritis, osteoarthritis and other inflammatory or connective-tissue disorders.

An Ayurvedic assessment of Amavata does not substitute for rheumatological assessment when RA is suspected. Delayed diagnosis and treatment may allow persistent inflammation and structural damage to progress.

AYURVEDIC MANAGEMENT PRINCIPLES AND AVAILABLE CLINICAL EVIDENCE

Ayurvedic management is traditionally individualized according to the person's presentation, disease stage, digestive status, strength and other clinical considerations. The principles below describe approaches discussed in Ayurvedic literature; their inclusion should not be interpreted as proof of efficacy for biomedical RA.

6.1 Nidana Parivarjana

Nidana Parivarjana refers to avoiding factors considered to contribute to disease. Dietary and lifestyle practices may be reviewed according to the individual's circumstances [1,2]. A clinical report has examined dietary measures alongside Virechana in patients described as having Amavata with reference to RA [6]. Findings from an individual study should be interpreted cautiously and cannot independently establish the effect of a specific intervention.

6.2 Langhana, Deepana and Pachana

Langhana, Deepana and Pachana are traditional management concepts used in relation to Ama-associated conditions [1,2]. Their use and intensity are described as dependent on the individual's condition. These concepts should not be assumed to correspond directly to established biomedical mechanisms, and restrictive dietary practices should not compromise nutritional adequacy.

6.3 Shodhana Chikitsa

Virechana and Basti procedures have been described or investigated in the management of Amavata. A study evaluated Matra Basti with Vatari Guggulu, while another investigated Alambushadi Ghana Vati with Vaitarana Basti in patients described as having Amavata with reference to RA [7,8]. These reports describe outcomes associated with particular treatment protocols, but differences in design, sample size, controls, outcome measures and follow-up limit the certainty and generalizability of their findings.

6.4 Shamana Chikitsa and Rasayana

Shamana approaches and selected Rasayana preparations have also been discussed in Ayurvedic management. A clinical study evaluated Vardhamana Pippali Rasayana in Amavata with reference to RA [9]. Such studies may inform further research, but they do not establish equivalence to DMARDs or demonstrate that these interventions prevent RA-related structural damage.

The safety of individual preparations and procedures must also be assessed, including potential adverse effects, product quality, interactions with conventional medicines and suitability for the individual. The evidence summarized here is not sufficient to make universal treatment recommendations.

DIETARY AND LIFESTYLE CONSIDERATIONS

Ayurvedic descriptions discuss diet and lifestyle in relation to Agni, Ama, Dosha and disease stage [1,2]. From a contemporary perspective, a balanced diet, physical activity adapted to ability, and appropriate support for maintaining function may contribute to general health in people living with RA. These measures should be individualized and used alongside, rather than instead of, appropriate medical treatment [5].

7.1 Pathya

Traditional Pathya recommendations should be individualized and remain nutritionally adequate.

Regular meals, suitable food choices, adequate hydration and physical activity within the person's capacity may be considered in light of their needs. Joint-mobility exercises and strengthening or aerobic activity should be adapted to disease activity and functional status, with professional guidance where appropriate.

7.2 Apathya

Dietary restrictions should not be unnecessarily broad or nutritionally inadequate. There is insufficient basis in the literature reviewed here to claim that avoiding particular foods treats RA or replaces medical therapy. Advice about diet and activity should take account of the individual's nutritional status, comorbidities, symptoms and clinical care plan.

CONTEMPORARY MANAGEMENT OF RHEUMATOID ARTHRITIS

The goals of RA management are to control inflammation, prevent or minimize structural damage, preserve function and improve quality of life. DMARDs are central to pharmacological management, with treatment adjusted to achieve remission or low disease activity [5]. The 2022 EULAR recommendations emphasize starting DMARD treatment promptly after RA is diagnosed. Methotrexate is a key component of the initial treatment strategy; alternative conventional synthetic DMARDs may be considered when it is contraindicated or not tolerated. Subsequent treatment depends on response, prognostic factors and safety considerations [5].

Glucocorticoids may be used in selected circumstances as short-term adjunctive or bridging treatment, with tapering and discontinuation as rapidly as clinically feasible when appropriate [5]. Treatment decisions should be individualized by qualified clinicians.

Ayurvedic interventions may be subjects for complementary research and, if a patient chooses to use them, should be discussed with the treating healthcare team. They should not delay assessment by a qualified clinician, replace indicated DMARD therapy, or lead to discontinuation of prescribed treatment without medical advice.

CURRENT RESEARCH EVIDENCE AND INTEGRATIVE PERSPECTIVES

9.1 Research on assessment of Ama

Research has attempted to develop structured approaches for assessing Ama in people described as having Amavata/RA. Pandey and colleagues developed and evaluated an Ama Assessment Instrument based on constitutional features. Their report described only a slight correlation between the Ama score and conventional measures including ESR and DAS28, while also examining changes over time [11]. These findings represent an early attempt to operationalize an Ayurvedic construct; they do not establish that the instrument is interchangeable with conventional measures of RA activity.

A subsequent study by Wagh, Joshi and Raut reported an association between Ama score and Clinical Disease Activity Index (CDAI), with a Spearman correlation coefficient of 0.6447 ($p < 0.0001$). The authors also reported differences in Ama scores between treatment-naive patients and patients in remission [12]. These findings warrant further evaluation and independent validation. Correlation does not demonstrate that the measures assess the same construct, establish causation, or prove treatment effectiveness.

9.2 Interpretation of intervention studies

Studies of Virechana, Matra Basti, Vaitarana Basti and Vardhamana Pippali Rasayana have reported clinical outcomes in patients described as having Amavata with reference to RA [6–9]. However, the studies differ in treatment protocols, study design, sample size and outcome measurement. The narrative evidence considered here does not permit a reliable pooled estimate of benefit or a conclusion that any intervention is equivalent to standard RA therapy.

9.3 Priorities for integrative research

Future studies should define the Ayurvedic diagnosis and biomedical RA diagnosis separately and specify how participants are classified. They should consider:

1. Reproducible diagnostic criteria for Amavata and clearly stated RA classification or diagnostic procedures.

2. Standardized and validated assessment of Ama and, where relevant, Agni.

3. Validated disease-activity measures such as DAS28 or CDAI, together with ESR, CRP where appropriate, functional outcomes and patient-reported symptoms.

4. Adequate sample sizes and appropriate control or comparison groups.

5. Prespecified outcomes, transparent statistical methods and sufficient follow-up.

6. Prospective recording of adverse events, treatment discontinuation and potential interactions with conventional medicines.

7. Reporting of intervention composition, dose, duration, treatment fidelity and product quality.

8. Assessment of whether any complementary intervention adds benefit without delaying or compromising evidence-based RA treatment.

DISCUSSION

This narrative review describes Amavata as an Ayurvedic framework in which Ama and aggravated Vata are central to the traditional explanation of joint manifestations [1,2]. Some features described in Amavata overlap with those of RA, including pain, swelling, stiffness and impaired function. Such overlap explains why RA is used as a clinical reference in some studies of Amavata, but does not establish diagnostic equivalence.

The distinction between the two frameworks is important for interpreting both clinical descriptions and treatment research. RA is a systemic inflammatory autoimmune disease assessed through clinical evaluation and supported by relevant laboratory and imaging investigations [3,4,10]. Its contemporary management emphasizes timely DMARD treatment and monitoring against a defined treatment target [5]. Traditional Ayurvedic concepts may be studied in their own terms, but should not be presented as biomedical mechanisms unless supported by appropriate evidence.

The clinical literature reviewed includes reports of selected Ayurvedic interventions [6–9]. However, the diversity of methods and outcomes, together with limitations in study design and follow-up, restricts the conclusions that can be drawn. Reported improvement in symptoms within an individual study does not, on its own, establish efficacy, long-term safety, prevention of structural damage or equivalence to standard treatment. Safety deserves specific attention because herbal preparations and procedures may have adverse effects or interact with prescribed medicines.

Research on Ama assessment offers a potential route for testing whether defined Ayurvedic features can be measured consistently and whether they provide useful information alongside established RA measures [11,12]. The reported relationships are not uniform and require replication in independent, diverse populations. Instruments should be assessed for reliability, validity, responsiveness and clinical utility before they are used to guide treatment decisions.

The practical implication is therefore cautious. People with persistent joint swelling, inflammatory pain or suspected RA need timely medical assessment and appropriate specialist care. Ayurvedic approaches may be investigated as complementary interventions where ethically and clinically appropriate, but they should not delay diagnosis or replace indicated DMARD therapy. A useful integrative research programme would combine clear diagnostic definitions, validated outcome measures, appropriate comparison groups and prospective safety monitoring.

LIMITATIONS AND FUTURE DIRECTIONS

11.1 Limitations

This article is a narrative review rather than a systematic review or meta-analysis. It does not report a comprehensive database search, duplicate screening, formal risk-of-bias assessment or quantitative synthesis; therefore, relevant studies may not have been identified and the review cannot establish the completeness of the evidence base. The included clinical literature is heterogeneous, with differences in sample size, design, intervention protocols, outcome measures and duration of follow-up [6–9]. Direct comparative evidence between Ayurvedic interventions and established RA treatment is limited.

A further limitation is the conceptual difference between Amavata and RA. Although certain manifestations overlap, the two are defined within different explanatory and diagnostic systems. Findings from studies using the term Amavata with reference to RA may not be generalizable to all people with biomedical RA unless diagnostic procedures are clearly described.

11.2 Future directions

Future research should include adequately powered, preferably multicentre controlled studies with clearly specified eligibility criteria, reproducible Ayurvedic assessments and appropriate biomedical diagnosis.

Standardized assessment of Ama should be evaluated alongside validated disease-activity measures such as DAS28 or CDAI, relevant laboratory markers, functional outcomes and patient-reported measures. Studies should include sufficient follow-up to evaluate sustained outcomes and should report adverse events, treatment interactions and withdrawals transparently.

Research should also assess whether complementary interventions provide additional benefit when used alongside standard care, without delaying or replacing indicated treatment. Independent validation of Ama assessment instruments across populations and clinical settings is necessary before wider clinical application can be recommended.

CONCLUSION

Amavata is an Ayurvedic concept in which Ama and aggravated Vata are central to the traditional explanation of joint symptoms. Its described manifestations, including pain, swelling, stiffness and functional limitation, overlap with some features of rheumatoid arthritis. However, Amavata and RA arise from distinct explanatory and diagnostic frameworks and should not be treated as identical conditions.

Published studies of selected Ayurvedic interventions and Ama assessment provide preliminary material for further investigation, but limitations in study design, sample size, standardization, outcome measurement and follow-up prevent definitive conclusions about effectiveness or equivalence to established RA treatment. Future studies should use reproducible Ayurvedic criteria, validated rheumatological outcomes and systematic safety monitoring. Appropriate medical diagnosis and evidence-based RA management remain essential; Ayurvedic approaches, where investigated or used, should not replace indicated specialist care or DMARD therapy.

DECLARATIONS

Ethical Approval: Not applicable. This narrative review does not involve recruitment of human participants or collection of primary patient data.

Informed Consent: Not applicable.

Funding: No external funding was received for the preparation of this manuscript.

Conflict of Interest: The author declares no conflict of interest.

Author Contributions: Dr. Neha Tiwari contributed to conceptualization, literature review, analysis and interpretation of the literature, and preparation, critical revision and final approval of the manuscript.

Data Availability: No primary datasets were generated or analyzed for this narrative review.

REFERENCES

1. Charaka. Charaka Samhita of Agnivesha with Ayurvedadipika commentary of Chakrapani Datta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2008.

2. Madhavakara. Madhava Nidana with Madhukosha commentary. Upadhyaya Y, editor. Varanasi: Chaukhamba Sanskrit Sansthan; 2005.

3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19. doi:10.1056/NEJMra1004965.

4. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-96. doi:10.1016/j.immuni.2017.02.006.

5. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356.

6. Gupta SK, Thakar AB, Dudhamal TS, Nema A. Management of Amavata (rheumatoid arthritis) with diet and Virechanakarma. Ayu. 2015;36(4):413-5. doi:10.4103/0974-8520.190688.

7. Khagram R, Mehta CS, Shukla VD, Dave AR. Clinical effect of Matra Basti and Vatari Guggulu in the management of Amavata (rheumatoid arthritis). Ayu. 2010;31(3):343-50. doi:10.4103/0974-8520.77167.

8. Sasane P, Saroj UR, Joshi RK. Clinical evaluation of efficacy of Alambushadi Ghana Vati and Vaitarana Basti in the management of Amavata with special reference to rheumatoid arthritis. Ayu. 2016;37(2):105-12. doi:10.4103/ayu.AYU_91_15.

9. Soni A, Patel K, Gupta SN. Clinical evaluation of Vardhamana Pippali Rasayana in the management of

Amavata (rheumatoid arthritis). Ayu. 2011;32(2):177-80. doi:10.4103/0974-8520.92555.

10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8. doi:10.1136/ard.2010.138461.

11. Pandey P, Rastogi S, Lawrence A, Agrawal GG. Development and validation of an ama instrument for assessing the disease activity on the basis of constitutional features in Amavata (rheumatoid arthritis). J Ayurveda Integr Med. 2023;14(2):100689. doi:10.1016/j.jaim.2023.100689.

12. Wagh S, Joshi V, Raut AA. Systemic Ama assessment and Clinical Disease Activity in patients with Amavata (rheumatoid arthritis). J Ayurveda Integr Med. 2026;17(4):101317. doi:10.1016/j.jaim.2026.101317.

Copy right & Licensing

© 2026 Dr. Neha Tiwari. Published by Ekansh Journal of Nursing, Public Health & Medical Sciences (EJNPH). This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/). The author retains copyright and full publishing rights without restrictions.